Feature | December 06, 2013

Stroke Mortality is Down, but the Reason Remains a Mystery

stroke treatment devices clinical trial study alabama
December 6, 2013 — A national group of leading scientists, including one University of Alabama at Birmingham (UAB) expert, said that for more than 100 years, fewer people have been dying of stroke, yet it is still unclear why this decline remains constant.
 
The American Heart Assn. (AHA) and American Stroke Assn. have published a scientific statement, “Factors Influencing the Decline in Stroke Mortality,” which has also been affirmed by the American Academy of Neurology as an educational tool for neurologists. The statement is published in the AHA journal Stroke.
 
Stroke is a leading cause of long-term disability and was previously recognized as the third leading cause of death in the United States, according to the National Stroke Association. However, stroke has now fallen to the fourth leading cause of death due to decreases in people dying from it. This has led the Centers for Disease Control and Prevention to acknowledge the decline and a similar decline in heart disease as one of the 10 great achievements in public health of the 20th century.
 
George Howard, Dr.P.H., professor, department of Biostatistics, School of Public Health, UAB, and statement co-author explained that, even with these dramatic decreases, there is still more to be done.
 
“Stroke has been declining since 1900, and this could be a result of changes leading to fewer people having a stroke or because people are less likely to die after they have a stroke,” said Howard. “Nobody really knows why, but several things seem to be contributing to fewer deaths from stroke.”
 
Perhaps the biggest contributor to the decline, Howard said, are changes leading to lower blood pressure levels, which is the biggest of the stroke risk factors. Other contributors may include reductions in smoking, better treatment of cholesterol and how people are cared for after having a stroke.
 
“We don’t know how much all of the sources are contributing,” said Howard. “Certainly, we want it to keep going down; but if we don’t understand why the numbers are decreasing, we can’t work toward that trend.”
 
Howard said that, in the last 11 years, stroke deaths have declined by 30 percent.
 
“It’s a big deal, so you could argue that our battle is won,” he said. “But I think we still have a lot to be accomplished in this area.”
 
Andrei Alexandrov, M.D., professor of neurology and director, UAB Comprehensive Stroke Center, was not affiliated with the statement but said it brings welcome news.
 
“This likely is attributable not only to better arterial blood pressure control over recent years, but also to a greater number of neurological specialists focused on stroke care across many hospitals in the United States and abroad,” said Alexandrov. “Better early stroke recognition and specialized care can also reduce the risk of dying from stroke.”
 
Alexandrov pointed out one finding of the statement — the lower death rate among adults younger than 65 years of age — deserves further attention since a large proportion of stroke victims in the Southeastern United States are young.
 
“More efforts are needed to reduce mortality and prevent first-ever stroke incidence, as well as to reverse disability following stroke by improving patient access to hospitals providing clot-busting therapy,” said Alexandrov.
 
Howard agrees that, while stroke prevention and care have played a large part in the decline of stroke mortality, more research needs to be done in stroke prevention.
 
“This brings up an interesting question: should more research resources go toward areas where we’ve seen success, or should they go where differences haven’t been made yet?” said Howard. “I’d say there’s an argument for both.”
 
For more information: www.uab.edu

Related Content

stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
Medtronic, Endurant Evo AAA, stent graft system, first European cases
News | Stent Grafts| August 13, 2015
Medtronic plc announced that the first two European patient cases with the Endurant Evo AAA stent graft system were...
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
ACC, Boehringer Ingelheim, Diabetes Collaborative Registry, American College of Cardiology
News | Cardiac Diagnostics| August 07, 2015
The American College of Cardiology (ACC) has announced that Boehringer Ingelheim is the newest industry sponsor of The...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
Boehringer Ingelheim, RE-DUAL PCI, RE-CIRCUIT, Pradaxa, first U.S. patients,
News | Antiplatelet and Anticoagulation Therapies| August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S.
Overlay Init